ArticleMolecular pharmacology2012
RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.
Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.Journal of nanobiotechnology · 2024Review
- Aptamers Targeting Membrane Proteins for Sensor and Diagnostic Applications.Molecules (Basel, Switzerland) · 2023Review
- Advances in Aptamer-Based Biosensors and Cell-Internalizing SELEX Technology for Diagnostic and Therapeutic Application.Biosensors · 2022Review
- A hotspot for enhancing insulin receptor activation revealed by a conformation-specific allosteric aptamer.Nucleic acids research · 2021Article
- Porous Silicon Nanoparticles Embedded in Poly(lactic-Advanced functional materials · 2020Article
- Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages.Molecular therapy. Nucleic acids · 2020Review
- Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines.Nature communications · 2018Article
- Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity.PloS one · 2018Article
- Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.Molecules (Basel, Switzerland) · 2017Review
- Review
- Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy.International journal of molecular sciences · 2016Review
- Cellular Delivery of RNA Nanoparticles.ACS combinatorial science · 2016Review
- In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs.Methods (San Diego, Calif.) · 2016Article
- Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation.Nucleic acids research · 2015Article
- Aptamer Selection Technology and Recent Advances.Molecular therapy. Nucleic acids · 2015Review
- Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Distinguishing closely related amyloid precursors using an RNA aptamer.The Journal of biological chemistry · 2014Article
- Current progress on aptamer-targeted oligonucleotide therapeutics.Therapeutic delivery · 2013Review
- Aptamers: problems, solutions and prospects.Acta naturae · 2013Article
- BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.Nature reviews. Neuroscience · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Many cell surface signaling receptors, such as the neurotrophin receptor, TrkB, have emerged as potential therapeutic targets for diverse diseases. Reduced activation of TrkB in particular is thought to contribute to neurodegenerative diseases. Unfortunately, development of therapeutic reagents that selectively activate particular cell surface receptors such as TrkB has proven challenging. Like many cell surface signaling receptors, TrkB is internalized upon activation; in this proof-of-concept study, we exploited this fact to isolate a pool of nuclease-stabilized RNA aptamers enriched for TrkB agonists. One of the selected aptamers, C4-3, was characterized with recombinant protein-binding assays, cell-based signaling and functional assays, and, in vivo in a seizure model in mice. C4-3 binds the extracellular domain of TrkB with high affinity (K(D) ∼2 nM) and exhibits potent TrkB partial agonistic activity and neuroprotective effects in cultured cortical neurons. In mice, C4-3 activates TrkB upon infusion into the hippocampus; systemic administration of C4-3 potentiates kainic acid-induced seizure development. We conclude that C4-3 is a potentially useful therapeutic agent for neurodegenerative diseases in which reduced TrkB activation has been implicated. We anticipate that the cell-based aptamer selection approach used here will be broadly applicable to the identification of aptamer-based agonists for a variety of cell-surface signaling receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.